Acquired In-Process Research and Development and Other Arrangements - Additional Information (Details)		3 Months Ended	12 Months Ended
	Feb. 10, 2023 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) target	Jul. 01, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses			$ 115,500,000	$ 1,113,300,000	$ 184,600,000
Catalyst Biosciences
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Asset acquisition, consideration transferred			60,000,000
CRISPR Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, right to exclusively license, number of targets | target						3
Collaborative arrangement development and regulatory potential milestone payments maximum						$ 410,000,000
CRSIPR A&R JDCA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum		$ 200,000,000
Up-front payment		$ 900,000,000
Allocation of net profits and net losses, percent							60.00%
CRSIPR A&R JDCA | CRISPR
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Allocation of net profits and net losses, percent							40.00%
Entrada Therapeutics | Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum	$ 485,000,000
Up-front payment	224,000,000
Purchase of common stock	$ 26,000,000
Verve
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum			340,000,000
Up-front payment			25,000,000
Purchase of common stock			35,000,000
Collaborative arrangement development and regulatory potential milestone additional payments			66,000,000
ApolLo1 Bio, LLC
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, milestone payment				15,000,000
Collaborative arrangement, option payment				60,000,000
Moderna Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement development and regulatory potential milestone payments maximum					380,000,000
Up-front payment					75,000,000
Mammoth Biosciences, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment				31,000,000
Arbor Biotechnologies, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment				25,000,000
Skyhawk Therapeutics Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Up-front payment					40,000,000
Additional In-License Agreements and Other Arrangements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Acquired in-process research and development expenses			$ 30,500,000	$ 138,300,000	$ 109,600,000